We are monitoring the impact of COVID-19 on Europe Antibody Drug Conjugates Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 5796
Share on
Share on

Europe Antibody Drug Conjugates Market Research Report - Segmented By pipeline, Technology, End User & Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic & Rest of Europe) - Industry Size, Share, Trends, Growth, Forecast | 2019 – 2024

Pulished: February, 2020
ID: 5796
Pages: 145

Europe Antibody Drug Conjugates Market Size & Growth (2019 – 2024):

As Per the Report, the Size of the Europe Antibody Drug Conjugates Market is valued at USD 2.47 billion in 2019 and estimated to be growing at a CAGR of 25.12%, to reach USD 7.56 billion by 2024 during the forecast period 2019-2024.

An antibody-drug conjugate(ADC) is a biologically active drug used as targeted therapy in the treatment of cancer that is highly potent drugs of the biopharmaceutical industry. These drugs are chemically complex molecules intended to kill the cancer cells in the body which composed of antibody that is biologically linked to anticancer drugs. These drugs target multiple pathways and reduce the risk of developing treatment-resistant disorders in the body.

By the mechanism of action, the drugs are segmented into IgG1 antibodies and HER2 antibodies which affect different pathogens like bacteria, fungi, and viruses in the body. Antibody-drug conjugates are widely accepting by several small and big pharmaceutical companies that is filling gaps between many oncology product pipelines. These drugs are also used in many other applications like metabolic disorders, cardiovascular, central nervous system, life science research tools, medical imaging, and vaccines.

Factors like rising in cancer incidences, changing lifestyles, high investments by the companies in the pipeline analysis, cancer-killing ability and research development of ADCs, growing biomedical industry, new product innovations and technological advancements are driving the Europe Antibody Drug Conjugates Market. However, the high cost of production of ADCs and stringent regulations for product approval are hindering the growth of the market.

Europe Antibody Drug Conjugates Market has been segmented and sub-segmented into the following categories 

  • By pipeline: Phase, Mode of action( Igg1 antibodies, HER2 antibodies), Technology, linker.
  • By Technology: Seattle genetics, Immunogen, Immunomedics.
  • By End User: Research institutes, Hospitals, Clinics.
  • By Country: UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic & Rest of Europe.

On the basis of region, Germany leads the global market, followed by France and U.K. The market in this region is projected to grow strongly during the forecast period due to various factors such as growing awareness and favourable reimbursement policies.

Prominent Companies dominating the Europe Antibody Drug Conjugates Market Profiled in the Report are Seattle Genetics, Genentech, Takeda Pharmaceuticals, F. Hoffmann-La Roche, Bayer Healthcare, Agensys, Inc., Immunogen, Novartis, Oxford Biotherapeutics, and Synthon Biopharmaceuticals.

1. Introduction        

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods 

                1.4 General Study Assumptions                

2. Research Methodology                  

                2.1 Introduction      

                2.2 Research Phases                      

       2.2.1 Secondary Research           

       2.2.2 Primary Research 

       2.2.3 Econometric Modelling      

       2.2.4 Expert Validation  

                2.3 Analysis Design

                2.4 Study Timeline 

3. Overview              

                3.1 Executive Summary                

                3.2 Key Inferences

                3.3 Epidemiology     

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)           

                4.1 Market Drivers 

                4.2 Market Restraints                    

                4.3 Key Challenges

                4.4 Current Opportunities in the Market     

5. Market Segmentation                     

                5.1 Pipeline Analysis                      

       5.1.1 Introduction           

       5.1.2 Phase        

       5.1.3  Mode of action    

                       5.1.3.1 IgG1 antibodies

                       5.1.3.2 HER2 antibodies

       5.1.4 Technology             

                       5.1.4.1 Seattle Genetics

                       5.1.4.2 Immunogen

                       5.1.4.3 Immunomedics

       5.1.5 Linker        

       5.1.6 Y-o-Y Growth Analysis, By Pipeline Analysis              

       5.1.7 Market Attractiveness Analysis, By Pipeline Analysis            

       5.1.8 Market Share Analysis, By Pipeline Analysis             

                5.2 End-user                      

       5.2.1 Introduction           

       5.2.2 Research institutes              

       5.2.3 Hospitals  

       5.2.4 Clinics        

       5.2.5 Others      

       5.2.6 Y-o-Y Growth Analysis, By End-user             

       5.2.7 Market Attractiveness Analysis, By End-user           

       5.2.8 Market Share Analysis, By End-user             

6. Geographical Analysis                     

                6.1 Introduction      

       6.1.1 Regional Trends    

       6.1.2 Impact Analysis     

       6.1.3 Y-o-Y Growth Analysis        

                       6.1.3.1 By Geographical Area

                       6.1.3.2 By Pipeline Analysis

                       6.1.3.3 By End-user

       6.1.4  Market Attractiveness Analysis     

                       6.1.4.1 By Geographical Area

                       6.1.4.2 By Pipeline Analysis

                       6.1.4.3 By End-user

       6.1.5  Market Share Analysis      

                       6.1.5.1 By Geographical Area

                       6.1.5.2 By Pipeline Analysis

                       6.1.5.3 By End-user

                6.2 U.K                 

                6.3 Spain    

                6.4 Germany                     

                6.5 Italy      

                6.6 France 

                6.7 Rest of Europe

7. Strategic Analysis              

                7.1 PESTLE analysis

       7.1.1 Political     

       7.1.2 Economic 

       7.1.3 Social         

       7.1.4 Technological         

       7.1.5 Legal          

       7.1.6 Environmental       

                7.2 Porter’s Five analysis     

       7.2.1 Bargaining Power of Suppliers        

       7.2.2 Bargaining Power of Consumers    

       7.2.3 Threat of New Entrants     

       7.2.4 Threat of Substitute Products and Services              

       7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis               

                8.1 Seattle Genetics                       

       8.1.1 Overview 

       8.1.2 Product Analysis   

       8.1.3 Financial analysis  

       8.1.4 Recent Developments       

       8.1.5 SWOT analysis       

       8.1.6 Analyst View          

                8.2 Genentech                 

                8.3 Takeda Pharmaceuticals                       

                8.4 F. Hoffmann-La Roche  

                8.5 Bayer Healthcare                     

                8.6 Agensys, Inc.,   

                8.7 Immunogen      

                8.8 Novartis                       

                8.9 Oxford Biotherapeutics

                8.10 Synthon Biopharmaceuticals   

9. Competitive Landscape                  

                9.1 Market share analysis   

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, Collaborations, and Joint Ventures

                9.4 New Product Launches

10. Market Outlook and Investment Opportunities                

Appendix                  

                a) List of Tables                

                b) List of Figures     

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • The segment-level analysis in terms Technology with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Europe Antibody Drug Conjugates  Market By Pipeline Analysis, From 2019-2024 ( USD Billion )
  2. Europe Phase Market By Region, From 2019-2024 ( USD Billion )
  3. Europe Mode of action Market By Region, From 2019-2024 ( USD Billion )
  4. Europe Technology Market By Region, From 2019-2024 ( USD Billion )
  5. Europe Linker Market By Region, From 2019-2024 ( USD Billion )
  6. Europe Antibody Drug Conjugates  Market By End-user , From 2019-2024 ( USD Billion )
  7. Europe Research institutes Market By Region, From 2019-2024 ( USD Billion )
  8. Europe Hospitals  Market By Region, From 2019-2024 ( USD Billion )
  9. Europe Clinics Market By Region, From 2019-2024 ( USD Billion )
  10. Europe Others Market By Region, From 2019-2024 ( USD Billion )
  11. U.K. Antibody Drug Conjugates  Market By Pipeline Analysis , From 2019-2024 ( USD Billion )
  12. U.K. Antibody Drug Conjugates  Market By End-user , From 2019-2024 ( USD Billion )
  13. Germany Antibody Drug Conjugates  Market By Pipeline Analysis , From 2019-2024 ( USD Billion )
  14. Germany Antibody Drug Conjugates  Market By End-user , From 2019-2024 ( USD Billion )
  15. France Antibody Drug Conjugates  Market By Pipeline Analysis , From 2019-2024 ( USD Billion )
  16. France Antibody Drug Conjugates  Market By End-user , From 2019-2024 ( USD Billion )
  17. Italy Antibody Drug Conjugates  Market By Pipeline Analysis , From 2019-2024 ( USD Billion )
  18. Italy Antibody Drug Conjugates  Market By End-user , From 2019-2024 ( USD Billion )
  19. Spain Antibody Drug Conjugates  Market By Pipeline Analysis , From 2019-2024 ( USD Billion )
  20. Spain Antibody Drug Conjugates  Market By End-user , From 2019-2024 ( USD Billion )

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample